Eli Lilly and Company
Explore Eli Lilly and Company
Core profile pages, annual revenue records, and related research hubs for this company.
CorpDigest
Eli Lilly and Company
Explore Eli Lilly and Company
Core profile pages, annual revenue records, and related research hubs for this company.
Annual Revenue
FY2021 Revenue
$28.3B
▲ 15.5% vs FY2020 ($24.5B)
Source: Annual report / company filing
Eli Lilly and Company reported $28.3B in revenue for fiscal year 2021. This represents a growth of 15.5% compared to the 2020 figure of $24.5B. In 2022, revenue increased to $28.5B.
Sales climbed 15.5 percent to $28.3 billion in 2021, reflecting steady demand across the diabetes and oncology portfolio ahead of the tirzepatide era.
| Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $65.2B | — | +44.8% |
| FY2024 | $45.0B | $10.6B | +31.9% |
| FY2023 | $34.1B | — | +19.6% |
| FY2022 | $28.5B | — | +0.8% |
| FY2021 | $28.3B | — | +15.5% |
| FY2020 | $24.5B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.